Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PRTA | US
0.19
0.95%
Healthcare
Biotechnology
31/03/2024
05/07/2024
20.26
19.93
20.36
19.55
Prothena Corporation plc a late-stage clinical company focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab a humanized monoclonal antibody which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005 which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and PRX123 a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease as well as TDP-43 and PRX019 for the treatment of Alzheimer's disease and other neurodegenerative diseases. Prothena Corporation plc has a license development and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin Ireland.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Price Below SMA10D
High Short-term Volatility
Smallcap (300M - 2B USD)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
59.7%1 month
52.0%3 months
51.3%6 months
63.1%-
64.10
2.13
0.02
0.02
-3.09
6.43
0.80
-215.30M
1.09B
1.09B
-
-163.06K
-
-97.70
-31.07
15.33
19.51
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
2.97
Range1M
3.88
Range3M
5.51
Rel. volume
0.58
Price X volume
6.75M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Day One Biopharmaceuticals Inc. Common Stock | DAWN | Biotechnology | 13.71 | 1.20B | 1.56% | n/a | 0.10% |
NRIX | NRIX | Biotechnology | 19.47 | 1.19B | 0.31% | n/a | 17.28% |
IRON | IRON | Biotechnology | 46.62 | 1.15B | 4.93% | n/a | 0.60% |
Sana Biotechnology Inc. Common Stock | SANA | Biotechnology | 5.09 | 1.13B | -2.49% | n/a | 28.28% |
4D Molecular Therapeutics Inc | FDMT | Biotechnology | 21.15 | 1.09B | 1.44% | n/a | 2.36% |
Tarsus Pharmaceuticals Inc | TARS | Biotechnology | 27.88 | 1.05B | -3.63% | n/a | 11.09% |
Calliditas Therapeutics AB | CALT | Biotechnology | 39.19 | 1.05B | -0.10% | n/a | 292.45% |
Ocular Therapeutix Inc | OCUL | Biotechnology | 6.67 | 1.03B | -0.30% | n/a | 18.24% |
Innoviva Inc | INVA | Biotechnology | 16.36 | 1.02B | 0.18% | 7.32 | 63.85% |
NRXPW | NRXPW | Biotechnology | 0.0836 | 994.03M | 4.50% | n/a | -44.99% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.36 | 1.14B | 1.60% | n/a | -628.58% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 17.73 | 799.13M | -2.42% | n/a | 4070.84% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 32.65 | 667.35M | -2.74% | n/a | 4.21% |
Ennis Inc | EBF | Building Products & Equipment | 21.25 | 552.16M | -0.75% | 13.68 | 1.15% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 4.48 | 428.47M | -2.40% | n/a | 138.85% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 25.77 | 412.92M | -1.68% | n/a | 322.60% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.74 | 369.15M | -2.49% | 14.12 | 86.68% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.36 | 324.63M | -2.40% | 10.10 | 0.00% |
Latham Group Inc. | SWIM | Building Products & Equipment | 2.74 | 316.67M | -3.52% | 75.75 | 80.81% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.55 | 298.02M | -0.34% | 8.24 | 25.57% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -3.09 | -2.43 | Cheaper |
Ent. to Revenue | 6.43 | 4,101.76 | Cheaper |
PE Ratio | - | 41.26 | - |
Price to Book | 2.13 | 22.34 | Cheaper |
Dividend Yield | - | 2.39 | - |
Std. Deviation (3M) | 51.29 | 76.52 | Lower Risk |
Debt to Equity | 0.02 | 0.51 | Cheaper |
Debt to Assets | 0.02 | 0.24 | Cheaper |
Market Cap | 1.09B | 3.77B | Emerging |